Novel pharmacologic approaches for the management of diabetic retinopathy

Molecular and Cellular Pharmacology

Volumn 1, Issue 4, 2009, Pages 222-227

  Kovach, Jaclyn L ^a   Schwartz, Stephen G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Corticosteroid; Diabetes; Diabetic retinopathy; Macular edema; Proliferative diabetic retinopathy; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DEXAMETHASONE; ETANERCEPT; FENOFIBRATE; FLUOCINOLONE ACETONIDE; HYALURONIDASE; HYBRID PROTEIN; I VATION; ILUVIEN; INFLIXIMAB; NEPAFENAC; OCTREOTIDE; OZURDEX; PLACENTAL GROWTH FACTOR; RANIBIZUMAB; RAPAMYCIN; RUBOXISTAURIN; TRAP EYE; TRIAMCINOLONE ACETONIDE; TRIESENCE; TRIVARIS; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; CATARACT; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DOSE COMPARISON; DRUG IMPLANTATION; ENDOPHTHALMITIS; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; PATHOPHYSIOLOGY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; UVEITIS; VITREOUS HEMORRHAGE;

EID: 77953465026     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.09.27     Document Type: Review

References (43)

1. US Centers for Disease Control and Prevention. National diabetes fact sheet:general information and national estimates on diabetes in the United States, 2005. Atlanta: Centers for Disease Control and Prevention, 2005.
2. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy and associated risk factors in type I diabetes. Ophthalmology 1998;105:1801-15.
3. Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
4. UK Prespective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type II diabetes. UKPDS 33. Lancet 1998;352:837-53.
5. Early Treatment Diabetic Retinopathy Study Resesarch Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806.
6. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981;88:583-600.
7. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-8.
8. Lam DS, Chan CK, Mohamed S, et al. A prospective randomized trial of different doses of intravitreal triamcinolone for diabetic macular edema. Br J Ophthalmol 2007;91:199-203.
9. Lam DS, Chan CK, Mohamed S, et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema:six month outcomes. Ophthalmology 2007;114:2162-7.
10. Kim JE, Pollack JS, Miller DG, et al;Isis Study group. ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema. Retina 2008;28:735-40.
11. Dehghan MH, Ahmadieh H, Ramezani A, et al. A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema. Int Ophthalmol 2008;28:7-17.
12. Bandello F, Polito A, Pognuz DR, et al. Triamcinolone as adjunctive treatment to laser photocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol 2006;124:643-50.
13. Three year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP et al. Arch Ophthalmol. 2009 Mar;127(3):245-51.
14. Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study groups. Am J Ophthalmol. 2007 Sep:144(3):454-6.
15. Hariprasad SM, CallananD, Gainey S et al. Cystoid and diabetic macular edema treated with nepafanac 0.1%. J Ocul Pharmacol Ther 2007;23:585-90.
16. Ducharme E, Weinberg JM. Etanercept. Expert Opin Biol Ther 2008;8:491-502.
17. Tsilimbaris MK, Panagiotoglou TD, CHarisis SK et al. The use of intravitreal etanercept in diabetic macular edema. Semin Ophthalmol 2007;22:75-9.
18. Sfikais PP, Markomichelakis N, Theodossiadis PG et al. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care 2005;28:445-7.
19. Ahmadieh H, Ramezani A, Shoeibi N et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo controlled trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483-9.
20. Scott IU, Edwards AR et al. Diabetic Retinopathy Clinical Research Network, A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:186-7.
21. Soheilian M, Ramezani A, Bijanzadeh B et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007;27:1187-95.
22. Paccola L, Costa RA, Folgosa MS et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular edema (IBEME study). Br J Ophthalmol 2008;92:76-80.
23. Shimura M, Nakazawa T, Yasuda K et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008;145:854-61.
24. Avery RL, Pearlman J, Pierimici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):1695-1705.e1-15.
25. Mirshahi A, Roohipoor R, Lashay A et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy:a randomized double-masked clinical trial. Eur J Ophthalmol 2008;18:263-9.
26. Arevalo JF, Maia M, Flynn HW Jr et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:213-6.
27. Rosenfeld PR, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
28. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
29. Chun DW, Heier JS, ToppingTM et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006;113:1706-12.
30. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Opthalmol. 2006;142:961-969.
31. Do DV, Nguyen Qd, Browning DJ et al. An exploratory study of the safety, tolerability and biological effect of a single intravitreal administration of vascular endothelial growth factor trap-eye in patients with diabetic macular edema. Br J Ophthalmol 2009;93:144-9.
32. Dejneka NS, Kuroki AM, Fosnot J et al. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 2004;10:964-72.
33. Kupperman BD, Thomas EL, de Smet MD, Grillone LR. Vitrase for Vitreous Hemorrhage Study Groups. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005;140:573-84.
34. Kupperman BD, Thomas EL, de Smet MD, Grillone LR. Vitrase for Vitreous Hemorrhage Study Groups. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005;140:585-97.
35. Lopez-Lopez F, Rodriguez-Blanco M, Gomez-Ulla F, Marticorena J. Enzymatic vitreolysis. Curr Diabetes Rev 2009;5:57-62.
36. Aiello LP. The potential role of PKC β in diabetic retinopathy and macular edema. Surv Ophthalmol 2002;47(Suppl 2):S263-9.
37. Donnelly R, Idris I, Forrester JV. Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research. Br J Ophthalmol 2004;88:145-51.
38. PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007;125:318-24.
39. Davis MD, Sheetz MJ, Aiello LP et al. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci 2009;50:1-4.
40. Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet 2007;370:1687-97.
41. Keech A, SImes RJ, Parter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):randomized controlled trial. Lancet 2005;366:1849-61.
42. Grant MB, Mames RN, Fitzgerald C et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy:a randomized controlled study. Diabetes Care 2000;23:504-9.
43. Boehm BO, Lang GK, Jehle PM et al. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 2001;33:300-6.